3rd Quarter - Amendment

HAGGERTY POLICY SOLUTIONS for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA User Fee Reauthorization Act of 2022 - Reauthorization of PDUFA, MDUFA, and BSFUA - Accelerated approval, clinical trial diversity, medtech issues such as change control plans and foreign inspections certificates COVID 19 supplemental and pandemic efforts Pharmacy Benefit Manager (BPM) transparency

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

R&D Tax Credit Reauthorization Orphan drug tax credit generally

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Inflation Reduction Act - all drug pricing provisions CMS proposed rule on Transitional Coverage of Emerging Technologies (TCET) Administration's EO on Prescription Drug Pricing

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Trade (domestic/foreign) TRD

Administration's support of WTO proposal on TRIPS waiver for COVID vaccines and therapies

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.